Datatrak's technology driven drug development (TD3) supports clinical trial industry transformation
![](/46/pdcnewsitem/03/87/12/datatrak.png)
Patient-focused models, improving adherence, and controlling costs all benefit from TD3.
Datatrak International has announced that more than 100 CROs, 10 of the top 15 pharmaceutical organizations, and 3 top 10 biotechs, are using the DATATRAK ONE UX platform in their efforts to harness technology to drive drug development.
"Technology Driven Drug Development, TD3, is the concept that underlies all technology in Datatrak's product solution portfolio. All of our customers look for every technological edge they can build into their processes. Maximizing the contribution of human and technological resources and consistently improving cost effectiveness is their daily routine. We're delighted that so many organizations are using the power of our DATATRAK ONE UX Platform to enable their success," said Laurence P. Birch, Datatrak CEO. He continued, "We're looking forward to helping the industry drive even greater efficiencies from patient-focused models, capturing big data, and using the resulting insight to increase the speed and efficacy of drug development."
Tim Lyons, Datatrak's Vice President of Product Development and Operations, stated that, "Our strategic investments in technology are moving the bar to help clinical operations capitalize on the viability of their drug pipelines. The DATATRAK ONE UX platform's capability to improve and easily configure workflows can make a huge difference as companies work to mitigate risk via adaptive trial design and risk based monitoring."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance